A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors. Protocol v.1.3

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

In Expansion Arm, participants must have one of the following genotypic mutations: RTK mutation, amplification or re-arrangement; KRAS-G12, BRAF Class 3 or NF1 LOF mutation.

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 18-1150

More information available at ClinicalTrials.gov: NCT03634982

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers